UCB to acquire maker of antibody treatments for autoimmune diseases

UCB is acquiring a maker of antibody treatments for autoimmune diseases, amidst tighter immigration policies in the US affecting international scientists and new funding for gene therapy startup Latus Bio. The acquisition highlights UCB's interest in expanding its portfolio of treatments for autoimmune diseases. This move may impact the biotech industry.